Сравнение

CagriSema vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	CagriSema	VK2735
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between CagriSema and VK2735?: CagriSema is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or VK2735?: The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and VK2735 in Germany and the United States?: Германия: CagriSema — Не одобрено, VK2735 — Не одобрено. США: CagriSema — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

VK2735

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between CagriSema and VK2735?

CagriSema is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or VK2735?

The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and VK2735 in Germany and the United States?

Германия: CagriSema — Не одобрено, VK2735 — Не одобрено. США: CagriSema — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.